SHINEWAY PHARM (02877) had a revenue of 2.415 billion RMB in the first three quarters, a decrease of 16.3% year-on-year.

SHINEWAY PHARM (02877) announces that as of September 30, 2025, the unaudited revenue for the first 9 months for the company and its subsidiaries is 2.415 billion RMB, a decrease of 16.3% compared to the same period in 2024, broken down as follows: - Revenue from injection products decreased by 23.6% to 0.786 billion RMB; - Revenue from soft capsule products decreased by 13.7% to 0.337 billion RMB; - Revenue from granule products decreased by 14.5% to 0.391 billion RMB; - Revenue from traditional Chinese medicine granule products decreased by 11.8% to 0.726 billion RMB; and - Revenue from other dosage forms decreased by 6.1% to 0.175 billion RMB. In terms of product types, as of September 30, 2025, revenue from injection products, soft capsule products, granule products, and traditional Chinese medicine granule products accounted for approximately 32.5%, 14.0%, 16.2%, and 30.1% of the group's total revenue, respectively.